Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18736150 | 1.00 | ALOX15 (0.56) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL12446349 | 1.00 | ALOX15 (0.56) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL12446352 | 0.91 | ALOX15 (0.48) | ALOX15ALDH1A1 | |
| SCHEMBL23707013 | 0.88 | ALOX15 (0.62) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL19919333 | 0.87 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL20734974 | 0.86 | ALOX15 (0.56) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL15727370 | 0.85 | ALOX15 (0.73) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL13176163 | 0.85 | ALOX15 (0.73) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL20734980 | 0.83 | ALOX15 (0.53) | ALOX15ALDH1A1GGPS1FDPSGLA | |
| SCHEMBL20735271 | 0.83 | ALOX15 (0.57) | ALOX15ALDH1A1GGPS1FDPSGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-12-19 | — | — | US | disclosed |
| CN-113024467-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-3770146-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ASTELLAS ENG SMALL MOLECULES US INCORPORATED (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-113004205-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| EP-3795566-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-109071459-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11358954-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-108349904-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113024467-A | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-113004205-A | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-06-22 | — | — | CN | disclosed |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200157074-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2020-05-21 | — | — | US | disclosed |
| WO-2017180818-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017062468-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157074-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
| US-11358954-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ALOX15 508/4885ALDH1A1 1587/4885GGPS1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.